OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	110.76	29.88	11.54
Cash & Short-Term Investments	110.76	29.88	11.54
Cash Growth	270.74%	158.82%	-
Prepaid Expenses	2.24	3.89	2.08
Total Current Assets	113	33.77	13.62
Property, Plant & Equipment	1.8	1.91	2.05
Other Long-Term Assets	0.11	0.06	0.33
Total Assets	114.91	35.73	16
Accounts Payable	2.97	3.42	2.52
Accrued Expenses	7.03	3.66	2.87
Current Portion of Leases	0.54	0.21	0.15
Total Current Liabilities	10.53	7.29	5.54
Long-Term Leases	0.55	0.47	0.49
Total Liabilities	11.08	7.75	6.03
Common Stock	0	-	0
Additional Paid-In Capital	258.55	0.21	2.66
Retained Earnings	-154.72	-102.05	-57.07
Total Common Equity	103.83	-101.84	-54.42
Shareholders' Equity	103.83	27.98	9.97
Total Liabilities & Equity	114.91	35.73	16
Total Debt	1.09	0.67	0.64
Net Cash (Debt)	109.68	29.2	10.91
Net Cash Growth	275.58%	167.76%	-
Net Cash Per Share	31.82	102.89	-
Filing Date Shares Outstanding	13.44	13.34	-
Total Common Shares Outstanding	13.35	13.34	-
Working Capital	102.47	26.48	8.08
Book Value Per Share	7.78	-7.63	-
Tangible Book Value	103.83	-101.84	-54.42
Tangible Book Value Per Share	7.78	-7.63	-
Machinery	1.05	1.01	0.85
Leasehold Improvements	1.09	1.09	1

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q